Processing

Please wait...

Settings

Settings

Goto Application

1. EP2425874 - Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]
Claims

1. A pharmaceutical composition comprising a vitamin D compound and an additional therapeutic agent for use in a method of treating a breast cancer.
  2. A product containing a vitamin D compound and an additional therapeutic agent as a combined preparation for simultaneous, separate or sequential use in a method of treating a breast cancer.
  3. A vitamin D compound for use in a method of treating a breast cancer, said method comprising administering the vitamin D compound in combination with at least one additional therapeutic agent; or a therapeutic agent for use in a method of treating a breast cancer, said method comprising administering the therapeutic agent in combination with a vitamin D compound.
  4. Use of a vitamin D compound in the manufacture of a medicament for a method of treating breast cancer, wherein the vitamin D compound is administered in combination with at least one additional therapeutic agent; or use of a therapeutic agent in the manufacture of a medicament for a method of treating breast cancer, wherein the therapeutic agent is administered in combination with a vitamin D compound.
  5. The pharmaceutical composition, the product, the vitamin D compound, the therapeutic agent or the use as claimed in claims 1 to 4, wherein the therapeutic agent comprises an anti-neoplastic agent, an alkylating agent, an anti-metabolite agent, an antibiotic agent, a hormonal ablation agent, an androgen ablation agent, an anti-androgen agent or a steroid.
  6. The product, the vitamin D compound, the therapeutic agent or the use as claimed in claims 2 to 4, wherein the vitamin D compound and the additional therapeutic agent are administered in a single composition comprising the vitamin D compound and the additional therapeutic agent.
  7. The product, the vitamin D compound, the therapeutic agent or the use as claimed in claims 2 to 4, wherein the vitamin D compound and the additional therapeutic agent are administered separately.
  8. The pharmaceutical composition, the product, the vitamin D compound, the therapeutic agent or the use as claimed in claims 1 to 4, wherein the vitamin D compound comprises seocalcitol and the therapeutic agent comprises mitoxantrone, paclitaxel, docetaxel, leuprolide, goserelin, triptorelin, abiraterone acetate, bicalutamide, flutamide, hydrocortisone, prednisone or dexamethasone.
  9. The pharmaceutical composition, the product, the vitamin D compound, the therapeutic agent or the use as claimed in claim 8, wherein amount of seocalcitol comprises about 0.1µg/day to about 500µg/day and the amount of the therapeutic agent comprises:

a. about 0.1mg/m2 to about 20mg/m2 of mixantrone, or

b. about 1 mg/m2 to about 175mg/m2 of paclitaxel, or

c. about 1 mg/m2 to about 100mg/m2 of docetaxel, or

d. about 0.01 to about 200mg of leuprolide over a period of about 3 days to about 12 months, or

e. about 0.01 mg to about 20mg of goserelin over a period of about 28 days to about 3 months, or

f. about 0.01 mg to about 20mg of triptorelin over a period of about 1 month, or

g. about 0.4mg/day to about 10,000mg/day of abiraterone acetate, or

h. about 1 mg/day to about 300mg/day of bicalcutamide, or

i. about 1 mg/day to about 2000mg/day of flutamide, or

j. about 10mg/day to about 250mg/day of hydrocortisone or prednisone, or

k. about 0.5mg/day to about 25mg/day dexamethasone.


  10. A vitamin D compound for use in a method of treating a refractory breast cancer in a patient who is currently receiving at least one treatment for cancer, the method comprising administering the vitamin D compound in addition to at least one treatment the patient is currently receiving.
  11. Use of a vitamin D compound in the manufacture of a medicament for a method of treating refractory breast cancer in a patient who is currently receiving at least one treatment for cancer, the method comprising administering the vitamin D compound in addition to at least one treatment the patient is currently receiving.
  12. The pharmaceutical composition, the product, the vitamin D compound, the therapeutic agent or the use as claimed in claims 1 to 4, 10 and 11, wherein the vitamin D compound comprises seocalcitol.
  13. The pharmaceutical composition, the product, the vitamin D compound, the therapeutic agent or the use as claimed in claims 1 to 4, 10 and 11, wherein the vitamin D compound comprises about 0.001µg/day to about 1000µg/day.
  14. The vitamin D compound or the use as claimed in claim 10 and 11, wherein the treatment for cancer comprises the administration of mitoxantrone, paclitaxel, docetaxel, leuprolide, goserelin, triptorelin, abiraterone acetate, bicalutamide, flutamide, hydrocortisone, prednisone or dexamethasone.
  15. The pharmaceutical composition according to claim 1 wherein the vitamin D compound is seocalcitol and the additional therapeutic agent is a steroid, and wherein the composition is suitable for oral administration.
 





REFERENCES CITED IN THE DESCRIPTION



This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description




Non-patent literature cited in the description



  • Remington: The Science and Practice of PharmacyMack Publ. Co. [0037]
  • HANSEN et al.Current Pharmaceutical Design, 2000, vol. 6, 803-828 [0045]
  • SABROE et al.Org. Proc. Res. Dev., 2004, vol. 8, 1133-135 [0045]
  • POSNER et al.Bioorg. Med. Chem., 2001, vol. 9, 92365-71 [0045]
  • GOODMAN & GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS20010000 [0059]
  • Journal of Pharmaceutical Sciences, 2005, vol. 94, 1830-1838 [0089]